EUVIMEDEUVIMED entdecken
Open Access

Development of Stable CHO-K1 Cell Lines Overexpressing Full Length Human CD20 Antigen

Niloufar Mohammadkhani, Azam Rahimpour, Reyhaneh Hoseinpoor, Masoumeh Rajabibazl

Iranian Biomedical Journal · 2023

DOI: 10.61186/ibj.27.5.269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iranian Biomedical Journal, 2023. Verfasst von Niloufar Mohammadkhani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Antigens, CD20, Genetic Vectors. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD20 is a differentiation-related antigen exclusively expressed on the membrane of B lymphocytes. CD20 amplification is observed in numerous immune-related disorders, making it an ideal target for immunotherapy of hematological malignancies and autoimmune diseases. MAb-based therapies targeting CD20 have a principal role in the treatment of several immune-related disordes and cancers, including CLL. Fc gamma receptors mediate CD20 internalization in hematopoietic cells; therefore, this study aimed to establish non-hematopoietic stable cell lines overexpressing full-length human CD20 antigen as an in vitro model for CD20-related studies.

Methods

CD20 gene was cloned into the transfer vector. The lentivirus system was transfected to packaging HEK 293T cells, and the supernatants were harvested. CHO-K1 cells were transduced using recombinant viruses, and a stable cell pool was developed by the antibiotic selection. CD20 expression was confirmed at the mRNA and protein levels.

Results

Simultaneous expression of GFP protein facilitated the detection of CD20-expressing cells. Immunophenotyping analysis of stable clones demonstrated expression of CD20 antigen. In addition, the mean fluorescence intensity was significantly higher in the CD20-CHO-K1 clones than the wild-type CHO-K1 cells.

Conclusion

This study is the first report on using second-generation lentiviral vectors for the establishment of a non-hematopoietic cell-based system, which stably expresses full-length human CD20 antigen. Results of stable CHO cell lines with different levels of CD20 antigen are well suited to be used for CD20-based investigations, including binding and functional assays.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD20Genetic VectorsCricetinaeAnimalsHumansCHO CellsCricetulus

Stichwörter der Autor:innen

CD20CHO cellsImmunotherapyLentiviral vector

Substanzen

Antigens, CD20

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran.
  • Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Mohammadkhani, N., Rahimpour, A., Hoseinpoor, R., & Rajabibazl, M. (2023). Development of Stable CHO-K1 Cell Lines Overexpressing Full Length Human CD20 Antigen. Iranian Biomedical Journal. https://doi.org/10.61186/ibj.27.5.269

Vancouver

Mohammadkhani N, Rahimpour A, Hoseinpoor R, Rajabibazl M. Development of Stable CHO-K1 Cell Lines Overexpressing Full Length Human CD20 Antigen. Iranian Biomedical Journal. 2023. doi:10.61186/ibj.27.5.269

BibTeX
@article{Mohammadkhani2023,
  author = {Mohammadkhani, Niloufar and Rahimpour, Azam and Hoseinpoor, Reyhaneh and Rajabibazl, Masoumeh},
  title = {Development of Stable CHO-K1 Cell Lines Overexpressing Full Length Human CD20 Antigen},
  journal = {Iranian Biomedical Journal},
  year = {2023},
  doi = {10.61186/ibj.27.5.269}
}
Kostenlos starten →